Trial Profile
A Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Nov 2021
Price :
$35
*
At a glance
- Drugs Regdanvimab (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man
- Sponsors Celltrion
- 11 Nov 2021 Status changed from recruiting to completed.
- 23 Aug 2021 Results published in the Clinical Therapeutics
- 11 Sep 2020 Interim results published in the Celltrion media release